Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS7305 in Primary IgAN, C3G, IC-MPGN and PMN
NCT07730632Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of QLS7305 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), primary membranous nephropathy (PMN), sponsored by Qilu Pharmaceutical. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
QLS7305
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07730632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730632.